Mice inoculated intranasally with a potentially lethal dose of HSV-1 (strain SC16) were used to evaluate the efficacy of penciclovir (PCV) and its oral form, famciclovir (FCV) in the treatmentof acute herpes encephalitis. In a comparative experiment, orally administered PCV was less effective than ganciclovir (GCV) in' reducing mortality of infected mice, but was of similar effectivenss to acyclovir (ACV). Late deaths from ongoing infections were observed following cessation of treatment with both ACV and FCV. Delaying the onset of treatment by more than 1 day post infection markedly reduced the ability of orally administered ACV, PCV, and FCV to prevent death. Treatment from day 1 with FCV administered ad libitum in the drinking water resulted in rapid clearance of infectious virus from all parts of the brain, but latent virus was detected by Southern blot hybridization in the peripheral and central nervous system of survivors 1 month post infection. In untreated mice, infectious virus was also detected in the epithelium of the turbinate bones and in the lungs from 1 day after intranasal inoculation, and acute inflammatory changes were seen in the lungs. FCV was more effective in clearing virus from the lungs than from the turbinate bones in these mice. These data, concerning the importance of virus replication in the respiratory tract with regard to subsequent encephalitis, are considered to be a novel aspect of this study. Received 
Introduction
HSV-1 is the major cause of sporadic acute encephalitis in the western world (Longson and Bailey, 1980; Brownell and Tomlinson, 1984) . Herpes simplex encephalitis (HSE) is a life-threatening disease, with a mortality exceeding 70% when untreated (Whitley, 1984) . To date adenine arabinoside (AraA) and acyclovir (ACV) have been the compounds most frequently used in the treatment of HSE (Whitley et al., 1977 (Whitley et al., , 1981 (Whitley et al., , 1983 (Whitley et al., , 1986 Skoldenberq et al., 1984) . The therapeutic potential of other compounds, such as bromovinyldeoxyuridine (BVDU) and ganciclovir (GCV) have been evaluated in murine models of HSE (deClercq et al., 1982; Heefschlaqer et al., 1982; Ashton et aI., 1982; Field et aI., 1984) . GCVin particular was found to be highly efficacious in clearing infectious virus from the brains of acutely infected mice (Field et al., 1984) .
The activity of the guanine derivative penciclovir (PCV, Fig. 1 ) against herpesviruses in cell culture and in animals has been described by Boyd et al. (1987 Boyd et al. ( , 1988 . PCV was shown to have a more persistent antiviral activity in cell culture than ACV, reflecting the greater stability of the triphosphate of PCV in infected cells compared with that of ACV, their respective half-lives being 10h and <1 h (Vere Hodge and Perkins, 1989) . PCV compared favourably to ACV in the treatment of mice infected with HSV-1 by various routes (Boyd et aI., 1988) . The present paper describes the effect of PCV and its oral form famciclovir (FCV, Fig. 1 ) on HSE established in mice by means of a potentially lethal intranasal dose of HSV-1, and their activity is compared with that of ACV and GCV. This model has been used previously for the evaluation of several antiviral agents (deClercq and Luczak, 1976; Field et al., 1984) and produces a pattern of infection similar to that seen in human HSE (Esiri, 1982; Anderson and Field, 1983) . The extent of respiratory infection in this model, which has not previously been described in detail, is also assessed, and the possible contribution of this to pathogenesis and successful chemotherapy is discussed.
Results

Comparison of PCv, ACV, and GCV
The efficacy or orally administered PCV in the treatment of acute HSE in mice was compared with that of two potent inhibitors of HSV-1; ACV and GCV. The fifty per cent effective dose (ED 50 ) value as determined by HSV-1 SC16 plaque reduction assay in Balb/C 3T3 cells were 0.02 f.Lg rnr ' for PCV, 0.01 f.Lg rnr "for ACV and 0.001 f.Lg mr"for GCV. Mice inoculated intranasally with a potentially lethal dose of HSV-1 SC16 were treated from either day 0 or day 1 post (p.i.) until day 8 p.i. (Table 1 ). All compounds were administered ad libitum in the drinking water. Infected, untreated mice began to show clinical signs by day 4 p.i, with no animals surviving beyond day 8 p.i, GCV was the most effective of the three compounds, conferring 100% survival irrespective of whether therapy was commenced at the time of infection or on the day after infection. Treatment with ACV or PCV was less effective than with GCV, and neither was fully protective against lethal disease. For both PCV and ACV, there were fewer survivors in the groups receiving treatment from day 1 p.i. than in those treated from the time of infection (63% compared with 87% for ACV, and 50% compared with 87% for PCV) (Table 1) . However, mean survival times were greater for mice treated with ACV than those treated with PCV. Latent infections were revealed in the trigeminal ganglia of some ACV-, PCV-, and GCV-treated survivors on day 87 p.i. by explant cultivation (Table 1) .
Two mice in the group receiving ACV from day 1 p.i, developed severe bilateral hindlimb paralysis on days 10 and 11 of the infection, and were close to death, having previously appeared free from clinical signs. Such a sudden clinical manifestation had not been observed in any of the other mice, who gradually became moribund prior to death. In order to ascertain whether the paralysis was a manifestation of late neurological sequelae following the clearance of infectious virus, or a result of ongoing virus replication, samples of tissue were taken on day 11 p.i. for titration. Infectious virus, indicative of an active infection, was detected in the olfactory lobes, trigeminal ganglia, brainstems, and cerebra of both mice. On histological examination of the cerebrum signs of acute encephalitis were seen, including lymphocytic meningitis and necrosis of the cortex ( Fig. 2a ) and vasculitis ( Fig. 2b ). Indirect immunoperoxidase staining revealed HSV-1 antigen-containing cells in affected areas of the cortex (Fig. 3) .
In a separate experiment, the effect of delaying PCV therapy was investigated ( Fig. 4 ). Treatment for 3 days beginning at the time of infection resulted in 93% survival (14/15 mice), whereas treatment delayed until day 3 p.i., was insufficient to prevent 100% mortality, even though PCV was provided in the drinking water until day 8 p.l,
Effect ot FCV treatment an intranasally infected mice
Infected mice were given 0.2 mg mr' FCV in the drinking water beginning at selected times after infection (Fig. 5 ). This type of investigation is highly relevant to the clinical situation, in which problems of early and accurate diagnosis hamper early commencement of therapy (Whitley et al., 1981) . In the untreated control group there were no survivors by day 9 p.i. Of the 20 mice receiving FCV from Table 1 . Effects of ACV. GCV. and PCV on mice intranasally infected with HSV-1. a Drugs were administered in drinking water ad libitum at 1 mg mr'. b Proportion of mice surviving for more than 28 days. C Treatment commenced at time of infection and continued until day 8. d Treatment commenced 1 day after infection and continued until day 8. e Two of the three mice that did not survive in this group were killed on day 11 p.i. suffering from severe bilateral hindlimb paralysis. f Proportion of left ganglia from survivors yielding infectious virus by the end of 9 days in vitro cultivation. The ganglia were explanted on day 87 p.I, For treatment started on days 1, 2, and 3, the proportions of surviving mice on day 19 p.i. were 70%,20%, and 10% respectively. Delaying the onset of therapy until day 2 p.i. or beyond therefore severely reduced the effectiveness of the treatment. In this experiment, FCV therapy starting on day 1 p.i. at an estimated dose of 40 mg kg-1 day" conferred 70% survival, compared to 50% survival conferred by an estimated five-fold greater dose of 200 mg kg-1 of PCV from day 1 p.i. (Table 1) .
Treatment"
None ACV c ACV d GCV c GCV" PCV c PCV d
Virus clearance from the peripheral and central nervous system during treatment with FCV
In order to provide more quantitative data on the efficacy of FCV in treating acute HSE, the extent of virus replication in various organs of the PNS and CNS of untreated and FCV-treated mice was measured. The commencement of treatment with 0.2 mg mr' FCV was delayed until day 1 p.i. as this was expected to result in sufficient survivors for study whilst ensuring that infection was underway before therapy began. Treatment was stopped on day 10 p.i.
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Untreated control mice were all dead by day 6, whereas 80% of the mice in the FCV-treated group survived the infection. No infectious virus was detected in the tissues of any mice on day 1 p.i. (Fig. 6 ), but was evident on day 2 p.i. in the olfactory lobes and cerebella of FCV-treated and untreated mice, and in the trigeminal ganglia and brainstems of untreated mice. Virus was ,not detected in the eyes and cerebra of mice from either group until day 4 p.i. The virus titres in all organs of untreated mice (except the eyes) peaked on day 4 or 5 p.i. The virus titres in organs from FCV-treated mice did not always peak correspondingly, but were at least 1 log10 lower than maximum titres from untreated controls at the height of the infection. The differences between mean virus titres of organs from untreated and FCV-treated mice was 1.4log 10 for trigeminal ganglia on day 4 p.i., 1.8 log10 for olfactory lobes on day 4 p.i., 2.1 log10 for brainstem on day 5 p.i., and 3.7 log10 for cerebrum on day 5 p.i. The percentage reduction (between untreated and FCV-treated groups) in virus titres summed over the first 6 days of the experiment, were (in decreasing order); day 1, eye and cerebrum (99%), day 2, brainstem (96%), day 3, trigeminal ganglia (94%), day 4, olfactory lobes (89%) and day 5, cerebellum (77%). No infectious virus was detected in any of the organs tested of any FCV-treated mouse after day 6 of the infection.
Detection of latent virus in the CNS and PNS of FCVtreated mice
Having shown that infectious virus was rapidly cleared from all parts of the brain as a result of treatment with FCV, it was of interest to ascertain whether any latent virus could be detected in the brains of survivors. Latent virus can be demonstrated in the ganglia of humans and experimentally infected animals by explant cultivation (Stevens and Cook, 1971; Stevens et aI., 1972; Baringer and Swoveland, 1973) , and HSV genomes in 'endless' form have been detected by Southern blot hybridization in the PNS and CNS of mice surviving sublethal infection (Rock and Fraser, 1983; Efstathiou et al., 1986) and in the trigeminal ganglia of humans (Efstathiou et aI., 1986) .
Although latent virus has been demonstrated in explanted trigeminal ganglia of mice following successful chemotherapy of HSV infections (Table1; Field et aI., 1984; Boyd et al., 1988) , we know of no reports of the detection of latent virus in the CNS tissues of such mice, either by explant cultivation or by Southern blot hybridization. FCV-treated survivors in the experiment described above were examined for the presence of latent virus on day 28 p.i. DNA samples from neural tissues of ten mice were pooled and digested with the restriction enzyme BamHI. The digests were analysed by Southern blot hybridization to a radiolabelled probe spanning the junetion region of the HSV-1 genome (Efstathiou et aI., 1986) . The probe hybridizes to three BamHI fragments of pure HSV-1 SC16 virion DNA present in the 1 copy per cell reconstruction ( Fig. 7, track 9 ), namely the K fjunction) fragment, and the Sand P (terminal) fragments. DNA extracted from the pooled brainstems of 3 acutely infected, untreated mice on day 4 p.i. was also included ( Fig. 7 , track 1) and contained both junction and terminal fragments of the HSV-1 genome at more than 2 copies per cell relative to the reconstruction. The cerebra, olfactory lobes, and trigeminal ganglia of the FCV-treated mice contain HSV-specific sequences corresponding to the junction region only (Fig. 7 , tracks 2, 5, and 6), a pattern indicative of the 'endless' HSV genomes seen in latently infected nervous tissue (Rock and Fraser,1983; Efstathiou et al., 1986) . On the original autoradiograph a faintly hybridizing band (not visible in the photograph) could be discerned in the track containing brainstem DNA (Fig. 7 , track 4). There was no evidence of HSV-specific sequences in the DNAfrom the pooled cerebella or eyes of drug treated mice, or from the brains of mock infected mice. It can be concluded that following the successful treatment with FCVof acute HSV-1 infection, the olfactory lobes, trigeminal ganglia, cerebra and probably brainstems of some or all of the surviving mice contain latent HSV-1 genomes.
Involvement of the respiratory system during the acute phase of infection
The extent of virus replication in respiratory tissues of mice intranasally inoculated with HSV-1 has not previously been investigated. A quantitative study of virus replication in the lungs and epithelium of the turbinate bones of untreated and FCV treated mice was made. FCV was administered at 0.2 mg rnl" in the drinking water from day 1 p.i. In this experiment, the inoculum dose was higher than in the previously described experiments and this determined by Student's t-test), The mean virus titres in lung, turbinate bones, olfactory lobe, and cerebrum are shown in Fig. 8 . In untreated mice, infectious virus was detectable as early as day 1 p.i. in all organs tested except cerebrum, the titres being highest in lung and turbinate bones. In the lung, virus tit res were at their peak on day 1 p.i. and declined gradually thereafter. The virus titres in the turbinate bones peaked on day 2 p.i. and remained high (10 4-105 p.f.u. sample-1) throughout all 5 days. In contrast, virus titres in olfactory lobes peaked later on day 4, while infectious virus did not appear in the cerebra of untreated mice until day 4. The mean infectivity tit res of organs from FCV-treated mice were, in most cases, between 0.5 log10 and 1.0 log10 lower than those of the corresponding organs in the untreated group. On day 4 p.i. all three of the untreated mice had infectious virus in their cerebra, but no virus could be detected in the cerebra of FCV-treated mice until day 5 p.i. The effect ofthe FCVwas most marked in the lungs, from which on infectious virus was detected after day 3 p.i. In turbinate bones and olfactory lobes however, FCV treatment failed to clear infectious virus by the end of the experiment. None of the mice showed any evidence of breathing difficulty, although many of the infected mice had a crusty exudate around the nares which was not observed in mock-infected mice. The lungs of mice in the infected, untreated group had patches of consolidation visible on the surfaces of some lobes from day 3 p.i. Pieces of the affected areas were taken for histological examination which revealed acute inflammatory changes. These included the presence of pulmonary oedema early in infection (Fig. 9b) , with later lymphocytic involvement of the bronchioles (Fig. 9c ).
Discussion
The present results were obtained using a model of -HSE involving intranasal inoculation of mice with HSV-1 SC16. The pathogenesis of this experimental infection has been accurately defined (Anderson and Field, 1983) , and is considered to be a relevant model of the human disease on the basis of antigen distribution in the brain (Esiri, 1982) . We have shown that oral treatment with FCV is effective in the treatment of experimental HSE. Successful treatment of HSE in mice with orally administered ACV has been shown to be dependent on early commencement of therapy (Field et al., 1984) , a finding also true of PCV and FCV, as demonstrated in this paper. PCV was of similar potency to ACV when administered in the drinking water at-1mg mr' (200mg kg-1 day-1) which is in agreement with the observations of Boyd et al. (1988) in their study of mice infected intranasally with HSV-1. However it was also demonstrated (Boyd et al., 1988) that the blood bioavailability in mice of PCV was up to 8-fold lower than ACV after equal oral doses, and the derivative FCV was therefore selected to improve the bioavailability of PCV (VereHodge et aI., 1989) .
In the present study, the antiviral effect against HSE of a dose of 1 mg mr' PCV (200mg kg-1 day-1) was comparable with that of a dose 0.2 mg rnr' (40mg kg-1 day-1)
FCV. This presumably reflects the fact that peak blood levels of PCV are greater than 10-fold higher in mice treated with FCV than in mice given an equivalent oral dose of PCVitself (Harnden et aI., 1989) .As expected from previous studies (Field et al., 1984) , GCV gave the greatest protection against death of all the compounds studied. This reflects the potent activity of GCV against HSV-1 in mouse cells, its ED so being 10 times lower than that of PCV. In addition, the incidence of ganglionic latency in survivors that had received GCV was lower than in survivors that had received ACV or PCV (Table 1) . However, the groups of mice used in this experiment were too small to allow rigorous quantitative analysis of the relative abilities of ACV, PCV, and GCV to prevent the establishment of ganglionic latency in this model. Administration of the compounds in all experiments quoted was by incorporation in the drinking water and mice were allowed to drink at will. There was no significant variation in the amounts consumed, and estimates of the total daily dose were calculated by volumetric difference.
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For some compounds, for example ACV (Field et al., 1984) , it is necessary to maintain the blood levels of the drug throughout the first few days of infection. This can be most readily achieved by administration in the drinking water. For PCV, however, it has been shown that single daily subcutaneous doses were at least as effective against HSE as administration in the drinking water (Boyd et aI., 1988) , suggesting that a lower frequency of dosing will be possible with PCV in comparison with ACV. This is presumably a consequence of the much greater stability of the intracellular triphosphate of PCV in virus-infected cells in comparison with that of ACV (Vere Hodge and Perkins, 1989) .
In two separate experiments, late deaths among drugtreated mice were observed. These were of sudden onset in previously asymptomatic mice, and occurred in days 10 and 11 in one group of ACV-treated mice (Table 1) , and on day 18 in a group of FCV-treated mice (group 1, Fig. 5 ). Infectious virus was detected in the brain tissues of the ACV-treated mice, and histological examination of their cerebra revealed signs of acute encephalitis. It may be that during chemotherapy, HSV persists as a sub-acute infection, and eventually causes late onset disease after the Cessation of treatment.
A quantitative study of virus replication in neural tissues revealed that treatment with FCV from day 1 to day 10 resulted in complete clearance of infectious virus from all parts of the brains of survivors by day 7 p.i. Over the first 6 days of the experiment, the greatest difference in peak virus titres between untreated and treated groups were seen in cerebrum and eye, and the least difference in olfactoy lobes and cerebellum. The reduction in virus titres within the eye after treatment with FCV was particularly marked.
An important finding was the detection of latent virus genomes in the pooled olfactory lobes, trigeminal ganglia, brainstems and cerebra of FCV-treated survivors by Southern blot hybridization. Previously, latent virus has been reactivated from the explanted trigeminal ganglia Of drug-treated survivors (Field et aI., 1984) , but this is the first report of the detection of latent virus in CNS tissues using this model. Field et al. (1984) failed to detect Viral sequences in the olfactory lobes, trigeminal ganglia or brainstems of GCV-treated survivors, although this could have been due to the limited sensitivity of tlie hybridization technique at low viral genome copy number per cell. It can be concluded therefore, that the clearance of infectious virus to undetectable levels in neural tissues during chemotherapy does not preclude the establishment of viral latency in the CNS. Latent virus in the CNS is an acknowledged source of recurrent infection following experimentally induced reactivation in animals (Sekizawa and Openshaw, 1984; Martin and Suzuki, 1989; Stroop et al., 1990) , and a large proportion of clinical cases of HSE are known to arise in patients who are already seropositive for HSV-1, and are therefore presumed to be recurrences of a primary infection (Nahmias et aI., 1982) . Residual latent virus in the PNS and CNS of survivors following chemotherapy is, in theory, therefore a potential source of recurrent infection. The experimental reactivation of virus from mice surviving HSE as a result of FCV treatment is now the subject of further study.
Little attention has been focused on the involvement of the respiratory tract following intranasal inoculation of mice with HSV-1. Anderson and Field (1983) found patchy necrosis of the respiratory epithelium and virus antigen within epithelial cells, but made no quantitative study of virus replication in nasal epithelium or lung. Following intranasal inoculation with HSV-1, infectious virus could be detected in the lungs and epithelia of the turbinate bones of mice, as well as in the tissues of the CNS and PNS (Fig. 8 ). Where seen, pathological involvement of the lung was patchy however, and did not overtly affect the breathing pattern of the mice. Virus titres in the lungs declined gradually during the first 5 days of infection and were considerably reduced in mice treated with FCV; infectious virus was completely cleared from the lungs in . the FCV-treated group by day 4 p.l, These observations correspond well to those of Kern et al. (1982) and Datema et al. (1987) who both detected virus in the lungs of mice following intranasal inoculation with HSV-2, and reported its rapid clearance following treatment with ACV. It can be concluded that lung involvement is unlikely to have been the sole cause of mortality in this experiment. Virus titres in the turbinates were extremely high given the small volume of the sample, peaked early and remained at fairly high levels throughout the first 5 days of the infection.
Thus, while it is likely that HSV-1 replication in the lung is not a major contributor to morbidity and mortality in intranasally infected mice, the significant and prolonged virus replication in the nasal epithelium of the turbinate bones may provide a continuous source of infectious virus early in the infection, over and above the inoculum virus itself. In other words, it may be the extensive primary virus replication at a peripheral site, and not merely the inoculum virus that ensures spread to the CNS by the olfactory route. This hypothesis is supported by the observation that virus was not detected in the cerebra of untreated mice until day 4, by which time replication in the turbinate bones had peaked (on day 2) and was also well underway in the olfactory lobes. Furthermore, virus was not detected in the cerebra of FCV-treated mice until day 5 p.i., a delay possibly due to the lower titres seen in the nasal epithelia of these mice.
It may therefore be failure to control virus replication at peripheral sites that accounts for the poor performance of orally administered PCV and FCV, when the start of treatment is delayed until 2 days p.i. If this is the case, any
Effects of PCV and FCV on HSV-1 encephalitis in mice 45 treatment regime that can successfully limit replication in the nasal epithelium of mice should prevent extensive seeding of the CNS and lessen the severity of subsequent encephalitis. Among the postulated routes of spread in human HSE are the olfactory (Dinn, 1980) and trigeminal (Davis and Johnson, 1979) pathways (the latter being mainly implicated in rare brainstem encephalitis). The olfactory pathway has been described in various animal models of HSE beside that under discussion here (Tomlinson and Esiri, 1983; Stroop etal., 1984; Schlitt etal., 1986) . If extensive virus replication in the nasal mucosa or any other peripheral site can give rise to HSE in man this may provide another reason to initiate chemotherapy at the earliest possible stage of disease. Our results suggest that early chemotherapy may help to limit the extent of neurological involvement via the olfactory pathway, as well as controlling cell to cell spread of virus within the CNS itself. There are however, many difficulties associated with early and accurate diagnosis of HSE (Whitley et al., 1981) , and it is to be hoped that recently developed techniques, such as the detection of minute quantities of viral DNA in cerebrospinal fluid (Boermann et al., 1989; Rowley et al., 1990) , will facilitate diagnosis.
Materials and experimental procedures
Virus
The virus used was HSV-1 strain SC16 (Hill et aI., 1975) . Infectivity was measured by plaque assay in BHK-21 cells.
Antiviral agents
Acyclovir (ACV,9-(2-hydroxyethoxymethyl)guanosine) and ganciclovir (GCV, 9-(1,3-dihydroxy-2-propoxy-methyl)guanosine) were supplied by Dr P. Collins, Welcome Foundation Ltd, Beckenham, Kent. Penciclovir (PCV,9-(4-hydroxy-3-hydroxymethylbut-1-yl)guanine) and famciclovir (FCV, diacetyl-6-deoxy PCV) were prepared in the laboratories of SmithKline Beecham Pharmaceuticals, Epsom, Surrey. The compounds were stored in powder form at -20°c and diluted in the drinking water to 1 mg rnr ",or 0.2 mg mr"for FCV, for oral administration. The activity of the compounds against HSV-1 SC16 in Balb/C 3T3 cells was determined by plaque reduction assay using a method described elsewhere (Field, 1985) .
Mice
Three-week-old female Balb/C mice were purchased from Bantin and Kingman, Aldbrough, Hull, UK.
Animal experiments
Mice were infected at 4 weeks old. Virus was diluted in Eagle's Minimum Essential Medium (EMEM) (Gibco, Grand Island, NY, USA) without serum to give 10 6 pJ.u.Jinoculum which corresponds to 10 X LD so (ten times the 50% lethal dose) by this route.
Intranasal inoculation was achieved by applying 10 JLI of a virus suspension to the nares of lightly anaesthetized mice. Compounds were administered to mice in the drinking water at 1 mg mr ', which resulted in an average daily intake of approx. 200mg kg-1 (results not shown; the average weight of a Balb/c mouse at 4 weeks is 10 g). Mice set aside for the collection of cumulative mortality data were observed daily for clinical signs and death. Survivors were those mice living for at least 28 days p.i. Tissues from three mice per time point were assayed separately for infectious virus. Tissues were removed aseptically, frozen in liquid nitrogen, and stored at -70°C. Later, samples were homogenized in 1 ml EMEM, and dilutions of the homogenate applied to monolayers of BHK-21 cells. After incubation at 3rC for 2 d, the monolayers were fixed and stained, the plaques counted and mean virus titres were calculated for each tissue at each time point. For explant cultivation, individual trigeminal ganglia were dissected and immediately placed in EMEM with 5% new born calf serum and incubated at 37"C for 9 d. During this period, the supernatant was monitored for the appearance of infectious virus before ultimate homogenization and titration of the ganglia.
Histology
Pieces of tissue were fixed in buffered formol saline for light microscopy. Fixed. tissues were processed and stained with haematoxylin and eosin according to standard procedures. Indirect immunoperoxidase staining was performed using rabbit anti-HSV-1 SC16 and the SIH Universal anti-rabbit kit (Sigma Chemical Co. Ltd, Poole, Dorset). Uninfected tissue was used as a negative control, and no staining of infected material was seen with pre-immune rabbit serum.
Southern blot hybridization
10 JLg high molecular weight DNA extracted from mouse neural tissues was digested with Bam HI, resolved on an 0.8% agarose gel and transferred to a nitrocellulose filter by the method of Southern (1975) as described by Maniatis et a/. (1982) . The probe consisted of part of the junction-spanning BamHI K fragment of HSV-1 strain KOS purified from plasmid pBKSP1 (kindly provided by S. Efstathiou). The probe was labelled with [et-3 2 PjdCTP by random priming. The nitrocellulose filter was prehybridized at 70°C for 5h in 2x Denhardt'ssolution, exSSC, 10mM phosphate buffer, 0.5% SDS and 100mg mr' denatured calf thymus DNA Hybridization was performed overnight at 70°C in 3x Denhardt's solution, 4x SSC, 10mM phosphate buffer, 0.5% SDS, 10% dextran sulphate and 100mg rnr' denatured calf thymus DNA Washes were performed at 70°C in 1 x Denhardt's solution, sx SSC, 10mM phosphate buffer, 0.5% SDS and 10mg mr' denatured calf thymus DNA for 20 min; 1x Denhardt's solution, 1x SSC, 10mM phosphate buffer, 0.5% SDS and 100mg mr ' denatured calf thymus DNA for 20 min, and 0.1 x SSC and 0.5% SDS for 1 h. Autoradiography was carried out at -70°C using Fuji RX film and light intensifying screens.
